Project Grant R21AI193598
Award Date 8/4/25
Completion Date 7/31/27
Dollars Obligated $502K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
- This $516,175 Project Grant was awarded on June 23, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant was awarded to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to evaluate the impact of pre-existing humoral immunity on hepatocyte death in the context of malaria. The research aims to explore how pre-existing immunity to malaria may...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $406,450 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Harvard T.H. Chan School of Public Health. The grant supports research to develop a continuous in vitro culture system for the Plasmodium vivax malaria parasite. Key objectives include optimizing the production of host reticulocytes (young red blood cells) to support P. vivax growth, iteratively improving culture conditions...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $489,500 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on July 24, 2025. The grant will fund structural studies of the full-length nucleocapsid (N) protein of SARS-CoV-2, the virus that causes COVID-19. The goal is to determine the high-resolution structure of the full-length N protein in complex...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,330 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research focused on improving antibody-based protection against Plasmodium falciparum (P. falciparum) and Plasmodium vivax (P. vivax) malaria. The project aims to identify new antibody variants with at least...
- This federal Project Grant award of $791,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify molecular factors controlling chromatin organization and gene regulation in the malaria parasite Plasmodium falciparum. The research aims to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and sexual differentiation, with the goal...
- This $423,500 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to examine the role of invariant natural killer T (iNKT) cells in driving pathogenic T cell responses in experimental cerebral malaria. The research aims to determine how the T cell receptor (TCR) mechanosensing properties of iNKT cells shape the development of CD8 T cell-mediated pathology in Plasmodium infection. The grant...
- This $244,440 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), to support a study examining the role of cytolytic ZEB2+ memory CD4+ T cells in providing protection against liver stage malaria. The research, conducted by Albert Einstein College of Medicine in Bronx, NY, aims to gain insights into the cellular immune determinants associated with natural clinical...
- This $1,174,636 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) supports the development of next-generation ELQ compounds for the treatment and prevention of malaria. The research aims to identify novel, rapidly acting anti-malarial drugs to target the blood and liver stages of the Plasmodium falciparum parasite, as well as formulations suitable for long-acting...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,808 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis, Missouri. The funding will support research to identify heme-binding proteins in the malaria parasite Plasmodium falciparum and investigate their role in maintaining heme homeostasis. The project aims to better understand how the parasite detoxifies heme, an essential but redox-active...